study question: Are genetic polymorphisms, previously identified as being associated with age at menopause in the healthy population, associated with ovarian reserve and predicted age at menopause in adult long-term survivors of childhood cancer?
Introduction
A well-known long-term side effect of cancer treatment in survivors of both adult and childhood cancer is gonadotoxicity (Lie Fong et al., 2008 ). The extent of gonadal damage depends on the treatment modality and the total cumulative dose (Sklar et al., 2006; Lie Fong et al., 2009; van Casteren et al., 2009; van Dorp et al., 2012) . In addition, the multi-drug approach may have a cumulative toxic effect on reproductive function (Wallace et al., 2005; van Beek et al., 2007) .
Along with these iatrogenic variables, the genetic variation of individuals together with environmental influences (e.g. smoking) determines an individual's reproductive health. Hence, fertility can be regarded as a complex trait that is a result of the interplay between a person's genetic make-up and the environmental disruptors to which one was exposed.
In the general population, the age at natural menopause varies between 40 and 60 years, with a mean of 50 -51 years, and is largely heritable (te Velde and Pearson, 2002; Murabito et al., 2005) . Associations between age at menopause and variants of genes involved in DNA repair, DNA maintenance and immunity have been previously identified in large genome-wide association (GWA) studies (Stolk et al., 2009 (Stolk et al., , 2012 He et al., 2010) .
Serum anti-Müllerian hormone (AMH) has been found to be a marker of the ovarian reserve. It is produced by granulosa cells of small, growing follicles in the ovary and is measurable in blood (de Vet et al., 2002) . It has been described as a useful serum marker of the ovarian reserve in mice (Kevenaar et al., 2006) , healthy women (de Vet et al., 2002) and adult survivors of childhood cancer (Lie Fong et al., 2009) . Recently, serum AMH levels were found to be highly predictive for the onset of menopause in healthy women (van Disseldorp et al., 2008; Freeman et al., 2012a,b) . Two nomograms to predict the age at menopause have been reported (Broer et al., 2011; Tehrani et al., 2011) : in these studies, AMH and age were significantly correlated with the time to menopause, and therefore included as predictors in the prediction models.
Variation of long-term toxicity in childhood cancer survivors (CCSs) who received the same treatment suggests that, besides environmental factors, genetic variation may influence the impact of late effects. In male adult CCSs, genetic polymorphisms in the estrogen receptor were associated with an increased risk of azoospermia (Romerius et al., 2011) . Data on the impact of previously identified variants in gene loci associated with the ovarian reserve in adult long-term CCSs are lacking. Since these genes may have an additive influence on the ovarian reserve (together with the effects of gonadotoxic treatment regimens), the aim of this pilot study was to evaluate whether the genetic polymorphisms known to be associated with menopause were associated with serum AMH levels, and together could predict the age at menopause in adult long-term CCSs.
Materials and Methods

Subjects
This retrospective study was performed in a single-centre cohort of female adult CCSs treated at the Erasmus MC-Sophia Children's Hospital from October 1962 to May 2001. Participants were 18 years and younger at the time of diagnosis, 18 -50 years old at the time of follow-up and in continuous complete remission. They had completed treatment at least 5 years ago. Participants were recruited during their regular visit at the late effects outpatient clinic. Only Caucasian females were included in order to minimize ethnic influences on the study outcome. Full details of cancer treatment were collected from the late effects clinic database and medical records, i.e. type and total cumulative doses of chemotherapy; site, field and cumulative dose of radiotherapy; extent of surgery; conditioning regimen prior to stem-cell transplantation; complications and relapses. The alkylating agent dose (AAD) score can be used to sum all alkylating agents that are known to be gonadotoxic. We calculated this score by determining the drug dose tertile distribution in our entire cohort of survivors independently and adding the tertile scores (1, 2 and 3) for each of the alkylating agents given to a particular patient, as previously used in CCSs (Tucker et al., 1987; Green et al., 2009 ) (Supplementary data, Table SI ). An AAD score of zero was assigned to patients not exposed to alkylating agents. A general health screening, including extensive history taking and physical examination, was performed. An official written informed consent was obtained from every patient who agreed to participate according to the standards of the Institutional Review Board.
Measurement of ovarian reserve
As most of our patients were of premenopausal age, a marker that is consistent during the menstrual cycle and representative of the ovarian reserve is needed. AMH is strongly correlated with the antral follicle count and is relatively constant during and between menstrual cycles, in contrast to FSH (Hehenkamp et al., 2006; La Marca et al., 2006; Tsepelidis et al., 2007; Streuli et al., 2008) . Therefore, AMH is a sensitive serum marker for the ovarian reserve and a proxy for menopause.
Serum samples were taken randomly during the menstrual cycle, in pregnant survivors as well as in survivors taking oral contraceptive pills or hormone replacement therapy. Serum AMH levels were measured with an in-house double-antibody enzyme-linked immunosorbent assay (de Vet et al., 2002; Kevenaar et al., 2006) . Intra-and inter-assay coefficients of variation were ,10 and ,5%, respectively (de Vet et al., 2002; Kevenaar et al., 2006) .
Genotyping
Single nucleotide polymorphisms (SNPs) were selected based on a literature search of previous candidate gene studies and more recently published GWA studies [for minor allele frequencies (MAFs), see Table I ]. We genotyped seven previously identified polymorphisms associated with age at menopause [BRSK1 (rs1172822) (Stolk et al., 2009) , ARHGEF7 (rs7333181) (Stolk et al., 2009) , MCM8 (rs236114) (Stolk et al., 2009 ), PCSK1 (rs271924) (He et al., 2010) , SRD5A1 (rs494958) (He et al., 2010) , IGF2R (rs9457827) (He et al., 2010) and TNF (rs909253) (He et al., 2010) ] in the samples from long-term CCSs.
Genomic DNA was extracted from peripheral blood using standard DNA extraction methods. 1 -2 ng of genomic DNA was dispensed into 384-well plates using a Caliper Sciclone ALH3000 pipetting robot (Caliper LS, Mountain View, CA, USA). Genotypes were determined using Sequenom iPLEX genotyping and Taqman Allelic Discrimination assays. All primers and probes are available on request.
Multiplex PCR assays were designed for the Sequenom iPLEX genotyping using Assay Designer on the website (https://mysequenom.com/ tools/genotyping/default.aspx). For this, sequences containing the SNP site and at least 100 bp of flanking sequence on either side of the SNP were used. As previously described (Stolk et al., 2009) , 2 ng of genomic DNA was amplified in a 5 ml reaction containing 1× Taq PCR Buffer (Sequenom), 2 mM MgCl 2 , 500 mM each dNTP, 100 nM each PCR primer and 0.5 U Taq (Sequenom). The reaction was incubated at 948C for 20 s, 568C for 30 s, 728C for 1 min, followed by 3 min at 728C. Excess dNTPs were then removed from the reaction by incubation with 0.3 U shrimp alkaline phosphatase (Sequenom) at 378C for 40 min followed by 5 min at 858C to deactivate the enzyme. Single primer extension over the SNP was carried out using a final concentration of 0.731 -1.462 mM for each extension primer (depending on the mass of the probe), iPLEX termination mix (Sequenom), 10× iPLEX Buffer Plus and iPLEX enzyme (Sequenom) and subsequently cycled using the following programme: 948C for 30 s followed by 948C for 5 s, five cycles of 528 for 5 s and 808C for 5 s, the previous three steps being repeated 40 times, then 728C for 3 min. This reaction was then desalted by the addition of 6 mg clear resin (Sequenom) followed by mixing (15 min) and centrifugation (5 min, 3000 rpm) to settle the contents of the tube. The extension product was then spotted onto a 384-well spectroCHIP using the SEQUENOM MassARRAY Nanodispenser RS1000 before analysis on the MassARRAY Compact System (Sequenom). Data were collected using SpectroACQUIRE 3.3.1.13 and clustering was called using TYPER Analyser 4.0.3.18 (Sequenom). Additionally, to ensure data quality, the genotypes for each subject were also checked manually.
Genotypes for rs236114 and rs909253 were generated using Taqman Allelic Discrimination (Applied Biosystems Inc., Foster City, CA, USA). Primer and probe sequences were optimized using the SNP assay-by-design service of Applied Biosystems (for details see www.appliedbiosystems.com). Reactions were performed on the Taqman Prism 7900HT 384-well format.
Statistical analysis
The SNPs were tested for deviation from the Hardy -Weinberg equilibrium (HWE) by comparing the observed and expected genotype frequencies using the x 2 test. AMH levels were studied as continuous measures and were divided in two groups based on levels considered to be clinically relevant and acting as a proxy for the ovarian reserve: serum AMH levels below 1 mg/l versus AMH levels equal to or above 1 mg/l. A x 2 test was used to analyse the associations between the SNPs and the two AMH groups. Association analyses were carried out and the additive genetic model was tested. First, we pooled heterozygous and homozygous carriers of the risk alleles under a dominant inheritance model. Linear regression was performed to calculate the effect of carrying the risk allele on continuous log-transformed AMH levels. Secondly, logistic regression was performed to calculate the odds ratio (OR) and 95% confidence intervals (CI) of the three genotypes (carriers of zero, one or two risk alleles) to assess risk, adjusted for age at AMH assessment, the AAD score and the total dose of radiotherapy to the pelvis. Analyses were not performed when the number of patients per genotype subgroup was below n ¼ 5. In view of the multiple comparisons, P-values of ≤0.0083 (0.05/6 SNPs) were considered to be significant.
We estimated the age at menopause based on serum AMH levels using two prediction models of the age at menopause based on a Dutch cohort and an Iranian cohort (Broer et al., 2011; Tehrani et al., 2011) . These prediction models are based on age and serum AMH levels. Subsequently, the effect of significant SNPs on this predicted age of menopause was evaluated using a linear regression model, adjusted for the AAD score and abdominal radiotherapy dose. P-values ≤0.05 were considered statistically significant. Statistical analysis was performed using the Statistical Package for the Social Sciences 17.0 software (SPSS, Chicago, IL, USA).
Results
The cohort of CCSs consisted of 238 women, of whom 5 died during follow-up, 6 were non-responders, 6 refused participation, 3 emigrated, 3 were disabled after treatment and 2 patients were .50 years. From the remaining 213 eligible subjects, serum AMH levels and DNA for genotyping were available in 192 survivors. Sixteen non-Caucasian survivors were excluded. Finally, 176 Caucasian women were included. The median age at diagnosis was 5.4 years, (range 0.1-16.8 years) in participants, and was comparable with the median age of survivors who discontinued follow-up and those in whom serum AMH levels or DNA samples were not available (median 6.7 years, range 0.8 -14.0 years, P ¼ 0.98). Neither the type of malignancy (P ¼ 0.08) nor the frequency of relapse (15 versus agents (54 versus 47%, P ¼ 0.48) or radiotherapy (34 versus 29%, P ¼ 0.44) differed between participants and non-participants, respectively. The median age at the time of cessation of treatment was 6.9 years (range 0.1 -17.8 years). The median age at follow-up was 24.8 years (range 18.0-46.2 years). Fifty-six survivors (32%) received chemotherapy and radiotherapy, 104 (59%) chemotherapy only 4 (2%) radiotherapy only and 12 (7%) surgery only. Twenty-three survivors (13%) were in second remission after relapse and six (3%) were in remission after a second malignancy. Eighty-nine survivors (51%) were treated with alkylating agents. Twelve survivors (7%) were treated with abdominal irradiation or total body irradiation.
At the time of inclusion, 48 of 176 survivors (27.3%) had regular menstrual cycles, whereas 15 survivors (8.5%) had oligo-or amenorrhoea. Three (1.7%) survivors were pregnant. In six survivors (3.4%), data on their menstrual cycle at the time of screening were not available. All other survivors used oral contraceptive pills (55.1%) or hormonal replacement therapy (n ¼ 7: 4.0%) at the time of follow-up. Table II presents the characteristics of the 176 female CCSs. Survivors were divided into two groups on the basis of AMH levels: a level below 1 mg/l (61/176: 35%) was considered to be low; a level equal to or above 1 mg/l (115/176: 65%) was considered to be normal. Age at diagnosis, age at the end of treatment, diagnosis and age at followup were not significantly different between the two AMH groups. As expected, significantly more survivors in the low AMH group were treated with abdominal irradiation or total body irradiation, and significantly more survivors in the normal AMH group were not treated with the known gonadotoxic alkylating agents. The median serum AMH level in all survivors was 1.8 mg/l (range ,0.1 -14.3 mg/l).
All polymorphisms were in HWE except for rs494958 (SRD5A1) ( Table I ). Consequently, this polymorphism was not used for comparison of allele frequencies and haplotype distributions in this study.
After correction for multiple testing, women with the CT genotype of rs1172822 had a significantly increased risk for a low serum AMH level (OR: 3.15, 95% CI: 1.35 -7.32, P ¼ 0. trend towards a higher risk of a low serum AMH level in women with the TT genotype (OR: 3.45, 95% CI: 1.06-11.27, P ¼ 0.04) (Table III) after correction for the age at AMH level, AAD score and abdominal irradiation. None of the other SNPs was associated with an increased risk for a low AMH. Using a carrier model, the T-allele of rs1172822 showed a borderline significant association with continuous serum AMH levels (b: 20.16, 95% CI: 20.62 to 20.06, P ¼ 0.017, Table IV ). This association may not be as significant as the analysis of the subgroups owing to the small number of patients (n ¼ 21) homozygous for the minor allele (T). Therefore, a linear regression of AMH levels and the three genotypes (CC, CT, TT) has been performed. A significant negative association between AMH and the heterozygote CT genotype of rs1172822 has been observed (b: 20.63, 95% CI 21.02 to 20.24, P ¼ 0.002), while no significant association between the TT genotype and AMH has been found (b: 20.47, 95% CI 21.06 to 0.13, P ¼ 0.123). We evaluated whether rs1172822 was associated with the predicted age at menopause using two menopause prediction models (Broer et al., 2011; Tehrani et al., 2011) . The rs1172822 polymorphism was negatively associated with predicted age at menopause using the Dutch population model (b: 20.17, 95% CI: 21.18 to 20.02, P ¼ 0.044) after adjustment for the AAD score and abdominal radiotherapy. However, the effect of treatment with alkylating agents or pelvic radiotherapy seemed to be larger than the effect of the polymorphism rs1172822 on the predicted age at menopause (Table V) . When we predicted the age at menopause based on the Iranian population model, we did not find a significant correlation with rs1172822 (b: 20.15, 95% CI: 25.94 to 0.42, P ¼ 0.088) ( Table V) . When performing analyses without adjustment for confounders, the rs1172822 was borderline significantly associated with predicted age at menopause in the Dutch population model (b: 20.64, 95% CI: 21.29 to 0.01, P ¼ 0.054) and was still not associated with age in the Iranian population model (b: 22.99, 95% CI 26.12 to 0.15, P ¼ 0.062).
Discussion
We evaluated the importance of SNPs, which had been shown previously to be associated with age at natural menopause in healthy women, to the ovarian reserve in female CCSs. We found that the CT genotype of rs1172822 of the BRSK1 gene was negatively Bold values significant at P , 0.0083 (after correction for multiple testing). OR, odds ratio; CI, confidence interval; RT, radiotherapy; CCSs, childhood cancer survivors. Multivariate analysis adjusted for age at AMH measurement, AAD score and abdominal radiotherapy. Cancer survivors and genetic effects on ovarian reserve associated with serum AMH levels after correction for multiple testing. Moreover, the T-allele of rs1172822 was associated with the predicted age at menopause of the Dutch population model. Serum AMH levels were used as a proxy for the ovarian reserve. As most of our patients were in the premenopausal age range, we needed a marker that does not fluctuate during the menstrual cycle and is representative of the ovarian reserve. AMH is strongly correlated with the antral follicle count and is relatively constant during and between menstrual cycles, in contrast to FSH (Hehenkamp et al., 2006; La Marca et al., 2006; Tsepelidis et al., 2007; Streuli et al., 2008) . Although some studies did report variations during the cycle (Wunder et al., 2008; Streuli et al., 2009; Sowers et al., 2010; Robertson et al., 2011) , the differences were small in amplitude and similar to the reported minor variability between cycles, which suggests that AMH production is independent of gonadotrophins. Therefore, AMH is a useful serum marker for the ovarian reserve. Moreover, two studies showed that serum AMH levels can be used to predict the age at menopause (Broer et al., 2011; Tehrani et al., 2011) , and therefore serum AMH levels were used in our study. An AMH level of 1 mg/l has been used as a cut-off value to identify a decreased ovarian reserve. Several studies have tried to identify a cut-off value for AMH to classify decreased fertility, poor response after IVF and non-pregnancy, and these studies have been reviewed (Broer et al., 2009) . The mean of these AMH cut-off values is 1 mg/l and we used this value as it is the best available estimate. However, we also performed our quantitative analyses with AMH levels and found a borderline significant association with the minor allele (T) of rs1172822. This association may not be as significant as the analysis of the subgroups owing to the small number of patients (n ¼ 21) homozygous for the minor allele (T). Therefore, a linear regression of AMH levels and the three genotypes (CC, CT, TT) has been performed. A highly significant negative association between AMH and the heterozygote CT genotype of rs1172822 has been observed (b: 20.63, 95% CI 21.02 to 20.24, P ¼ 0.002), which supports the negative association between rs1172822 and AMH levels.
A low serum AMH level in adult female CCSs was associated with the CT genotype of rs1172822, which is consistent with previous findings in healthy women in which this polymorphism was associated with a decrease in the age at menopause of 4 months per T-allele (Stolk et al., 2009; He et al., 2010) . Rs1172822 is a polymorphism in the BR serine/threonine kinase 1 gene (BRSK1), which is located on chromosome 19q13.4, intron 17 and encodes an AMP-activated protein kinase (AMPK)-related kinase. It is highly expressed in the human forebrain (Kishi et al., 2005) and moderately expressed in mammalian ovaries (GeneAtlas). Interestingly, the downstream targets of BRSK1 are several members of the family of AMPK-related kinases phosphorylate tau, a microtubule-associated protein that regulates the stability of the microtubule network (Kishi et al., 2005) . This includes the maternal embryonic leucine zipper kinase (MELK2; chromosome 9) that is highly expressed in spermatogonia and oocytes (Lizcano et al., 2004; Thelie et al., 2007) . BRSK1 is specifically activated by phosphorylation, together with 12 other AMPKs, including MELK, through the serine/threonine protein kinase 11, named STK11 or LKB1 (Bright et al., 2008) . LKB1 (19p13. 3) is considered a master regulator of cell polarity (by regulating cytoskeletal dynamics) and, being the only protein identified with this activity, it is expressed in mouse oocytes (Szczepanska and Maleszewski, 2005 (Lans and Hoeijmakers, 2012) . This may explain the involvement of BRSK1 in the ovarian ageing process, possibly resulting in reduced AMH levels. In the present study, only one of the six previously identified polymorphisms in the healthy population was associated with AMH levels in adult female CCSs. These findings suggest that the effects of gonadotoxic treatment exceed the influence of these genetic polymorphisms. However, most of these SNPs have a low MAF ( Table I ). The lower the MAF, the higher the number of survivors needed to achieve sufficient power to observe an influence on AMH levels. Therefore, final conclusions regarding these associations cannot be drawn, given the relatively small effect size of those polymorphisms and the large effect of alkylating agents and pelvic radiotherapy on the ovarian reserve in a small sample of CCSs. Our observations should be investigated further in a larger sample.
Rs1172822 is significantly associated with the predicted age at menopause of the Dutch population model by Broer et al. (2011) . This is in line with a previous report that the rs1172822 polymorphism is associated with the age at menopause in the healthy population (Stolk et al., 2009) . Still, the effect of treatment with alkylating agents or pelvic radiotherapy seemed to be stronger than the effect of the rs1172822 polymorphism on the predicted age at menopause. We found no association between rs1172822 and the predicted age at menopause using the Iranian population model: the different genetic background of the women in the Iranian population model is most likely the cause. Indeed, the rs1172822 MAF in Asian subjects is 10-fold lower than in the European population (dbSNP).
We realize that our pilot study only shows preliminary data. To confirm our findings and enlarge the study, a nationwide GWA project on the ovarian reserve in female CCSs should be performed, including a replication cohort.
In conclusion, we showed that the CT genotype of rs1172822 of the BRSK1 gene in female adult CCSs is associated with a decreased serum AMH level and a lower predicted age at menopause, based on a Dutch population model. These findings support the idea that previously identified polymorphisms which are associated with age at menopause in healthy women may also have an effect on the onset of menopause in female CCSs. This pilot study appears to show a new aspect of the influence of genetic variants on the ovarian reserve following treatment of childhood cancer and should be investigated further in a nationwide GWA study. Eventually, this information can help us to improve counselling on fertility preservation prior to cancer treatment, based on genetic factors in individual patients.
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